- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| BIOMX Aktie jetzt für 0€ handeln | |||||
| 09.06. | BiomX Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 16.05. | H.C. Wainwright cuts BiomX stock target to $15, maintains Buy | 6 | Investing.com | ||
| 15.05. | BiomX Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 15.05. | BiomX Inc. - 8-K, Current Report | 8 | SEC Filings | ||
| 15.05. | BiomX GAAP EPS of -$0.33 beats by $0.03 | 7 | Seeking Alpha | ||
| 15.05. | BiomX Inc. Bottom Line Retreats In Q1, But Beats Estimates | 1 | RTTNews | ||
| 15.05. | BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates | 92 | GlobeNewswire (Europe) | In March 2025, BiomX announced positive topline results of the phase 2 trial evaluating BX211 for the treatment of diabetic foot osteomyelitis (DFO) BX004 Phase 2b study in Cystic Fibrosis (CF) on... ► Artikel lesen | |
| 14.05. | A Look at BiomX's Upcoming Earnings Report | 5 | Benzinga.com | ||
| 23.04. | BiomX Inc. - 8-K, Current Report | 3 | SEC Filings | ||
| 11.04. | BiomX Inc. - S-1, General form for registration of securities | 3 | SEC Filings | ||
| 04.04. | H.C. Wainwright maintains BiomX stock Buy rating, $21 target | 12 | Investing.com | ||
| 01.04. | BiomX stock target soars to $21 on Phase 2 trial success | 2 | Investing.com | ||
| 01.04. | BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure | 125 | GlobeNewswire (Europe) | NESS ZIONA, Israel, April 01, 2025 (GLOBE NEWSWIRE) -- BiomX Inc. (NYSE American: PHGE) ("BiomX" or the "Company"), a clinical-stage company advancing novel natural and engineered phage therapies... ► Artikel lesen | |
| 31.03. | BiomX's bacteria-killing virus reduces diabetic bone ulcers in midstage test | 4 | FierceBiotech | ||
| 31.03. | BiomX Reports Positive BX211 Trial Results In Diabetic Foot Osteomyelitis; Plans Phase 2/3 Trial | 1 | RTTNews | ||
| 31.03. | BiomX reports progress in diabetic ulcer treatment | - | Investing.com | ||
| 31.03. | BiomX meldet Fortschritte bei der Behandlung von diabetischen Geschwüren | 3 | Investing.com Deutsch | ||
| 31.03. | BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO) | 126 | GlobeNewswire (Europe) | BX211 was safe and well-toleratedBX211 produced sustained and statistically significant1 Percent Area Reduction (PAR) of ulcer size (p = 0.046 at week 12; p=0.052 at week 13), with a separation from... ► Artikel lesen | |
| 25.03. | BiomX Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 25.03. | BiomX Inc. Full Year Profit Falls | - | RTTNews |
1 2 Weiter >>
33 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 90,70 | -0,60 % | Die nächste Cashcow? Schnelle Prozente mit NetraMark, Moderna, BioNTech | Erinnern Sie sich noch an den Impfstoff-Wettlauf in der Corona-Zeit? Damals bestimmte das Duell zwischen BioNTech und Curevac auch das Geschehen an der Börse. Anleger der ersten Stunde machten schnell... ► Artikel lesen | |
| AMGEN | 237,00 | +0,11 % | ROUNDUP/Aktien New York Schluss: Gewinne - 'Iran-Angriff eine Gesichtswahrung' | NEW YORK (dpa-AFX) - Der Nahost-Krieg hat am Montag die Richtung an den US-Börsen bestimmt. Die wichtigsten US-Indizes legten am Ende kräftig zu und erreichten kurz vor dem Handelsschluss Tageshöchststände.... ► Artikel lesen | |
| INOVIO PHARMACEUTICALS | 1,840 | +1,10 % | INOVIO Pharmaceuticals, Inc.: INOVIO Reports First Quarter 2025 Financial Results and Recent Business Highlights | On track to begin rolling submission of Biologics License Application (BLA) for INO-3107 as a potential treatment for recurrent respiratory papillomatosis (RRP)... ► Artikel lesen | |
| CARDIOL THERAPEUTICS | 1,304 | +8,49 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Reports Results of 2025 Annual General Meeting of Shareholders | Toronto, Ontario--(Newsfile Corp. - May 29, 2025) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on developing anti-inflammatory... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,099 | -0,67 % | Beyond The Numbers: 4 Analysts Discuss Pacific Biosciences Stock | ||
| REDHILL BIOPHARMA | 1,770 | -2,75 % | RedHill Biopharma Ltd. - F-1, Registration statement for certain foreign private issuers | ||
| FIBROGEN | 5,230 | -1,32 % | XFRA 1FG0: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILFIBROGEN INC. NEW... ► Artikel lesen | |
| LEXAGENE | - | - | LexaGene Holdings Inc. - REVOKED, Commission order revoking Exchange Act registration [Section 12(j)] | ||
| ALLAKOS | 0,255 | 0,00 % | XFRA DELETION OF INSTRUMENTS FROM BOERSE FRANKFURT - 15.05.2025 | The following instruments on Boerse Frankfurt do have their last trading day on 15.05.2025.Die folgenden Instrumente in Boerse Frankfurt haben ihren letzten Handelstag am 15.05.2025.ISIN NameCA05259R1073 AUSTRALIS... ► Artikel lesen | |
| VAXCYTE | 28,400 | +2,16 % | Vaxcyte, Inc.: Vaxcyte Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | -- Completed Successful VAX-31 Phase 2 Adult Program; Company Remains on Track to Initiate VAX-31 Adult Phase 3 Pivotal, Non-Inferiority Study by Mid-2025 and Announce Topline Safety, Tolerability... ► Artikel lesen | |
| VERRICA PHARMACEUTICALS | 0,470 | +2,49 % | Verrica Pharmaceuticals Inc.: Verrica Pharmaceuticals Appoints Noah L. Rosenberg, M.D., as Chief Medical Officer | WEST CHESTER, Pa., March 26, 2025 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. ("Verrica" or the "Company") (Nasdaq: VRCA), a dermatology therapeutics company developing medications for skin diseases... ► Artikel lesen | |
| HOOKIPA PHARMA | 1,250 | 0,00 % | HOOKIPA Pharma Inc. ("HOOKIPA") Statement regarding potential combination for Poolbeg Pharma plc ("Poolbeg") | NEW YORK and VIENNA, Austria, Feb. 20, 2025 (GLOBE NEWSWIRE) -- NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 2,395 | -0,62 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) | DALLAS, June 06, 2025 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen | |
| SOLID BIOSCIENCES | 4,720 | -1,87 % | Citi startet Berichterstattung für Solid Biosciences mit Kaufempfehlung | ||
| HARMONY BIOSCIENCES | 31,980 | +0,38 % | Mizuho reaffirms Harmony Biosciences stock rating on positive orexin data |
BIOMX INC gehört der Branche Biotechnologie an. Mit einer aktuellen Kursveränderung von -0,003 (-0,56 %) liegt der Kurs bei 0,448 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu BIOMX INC finden Sie auf Wallstreet Online.